Here, we studied immunogenicity of 2 out of 18 MBC antigens, namely, ZRF1 and KRR1, in sera of patients with breast tumors of different histological types and grades compared with sera of age-matched healthy donors using large-scale allogeneic screening performed by ELISA. This evidence concerns the gene DNAJC2 and breast neoplasm.